“As of September 30, 2024, the company had approximately $3.1 billion of Board approved share repurchase authorization remaining. On October 15, 2024, our Audit Committee, pursuant to authorization granted by the Board of Directors, authorized an $8.0 billion increase to the common stock repurchase program. The company intends to utilize this authorization over a multi-year period, subject to market and industry conditions.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Options Volatility and Implied Earnings Moves Today, October 17, 2024
- Elevance Health falls 11% to $441.06 after cutting FY24 adjusted EPS outlook
- Elevance Health reports Q3 adjusted EPS $8.37, consensus $9.66
- Elevance Health cuts FY24 adjusted EPS view to ~$33.00 from ‘at least’ $37.20
- Notable companies reporting before tomorrow’s open
Questions or Comments about the article? Write to editor@tipranks.com